Gapping up
In reaction to strong earnings/guidance: PDII +16.5%, GEVO +16%, TUBE +14.6%, HDP +11.7%, SYMX +10.9%, OPWR +10.3%, BIOC +7%, RENT +6.6%, ICCC +5.7%, CARA +5.6%, NVFY +5.5%, NEWR +5.3%, NVMI +4.7%, TSEM +4.6%, VIP +4.5%, ZBRA +3%, STKL +2.8%, ICL +2.3%, HCKT +1.9%, ELOS +1.9%, SSRI +1.8%, NAII +1.5%, MNGA +1.2%,VJET +1%, PCP +1%
M&A news: WPZ +26.1% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), OI +8.4% (acquires Vitro S.A.B's food and beverage business for $2.15 bln), WMB +8.4% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), WX +5.9% (forms special committee of independent directors to evaluate the previously announced proposed takeover transaction), DHR +5.8% (acquires PLL; Danaher announces intention to separate into two independent, publicly traded companies), PLL +4.9% (to be acquired by Danaher (DHR) for $127.20 per share), SPKE +1.9% (announces acquisition of Oasis Energy)
Select oil/gas related names showing strength: STKL +2.8%, SDRL +2%, SD +1.3%, TOT +1.3%, BP +0.9%.
Other news: FCSC +25.8% ( recieves rare pediatric disease designation for FCX-007 from the FDA, to treat recessive dystrophic epidermolysis bullosa), AMCF +8.7% (announced that its previously scheduled NASDAQ listing hearing was cancelled after co pays outstanding fees; announced business updates, including entery into a non-binding letter of intent with Three Pillars PetroChem), MAGS +7.3% (recieves two new orders, worth a total of $13 mln), VRTX +7.2% (confirmed FDA Advisory Panel voted 12 to 1 to recommend approval of ORKAMBI to treat people with cystic fibrosis ages 12 and older), NBG +5.1% (optimism with Greece situation), QSR +3.2% (announces an $1.2 bln offering of first lien senior secured notes due 2022), DAL +2.7% (announces a new $5 billion share repurchase program, and a dividend increase of 50% to $0.135/share beginning in the September, 2015 quarter), NRF +2% (still checking), PPO +2% (disclosed that at a special meeting, its stockholders approved the proposal to adopt the Agreement and Plan of Merger with Asahi Kasei), AXP +1.5% (authorizes repurchase of up to 150 mln shares, announces 12% dividend increase), JBLU +1.2% (reports its preliminary traffic results for April 2015), DEO +1% (peer SAB Miller reported bte results), SNY +1% (exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease under the terms of an existing strategic global collaboration with Selecta Biosciences), TASR +1% (announces recent multiple orders, including up to 460 X2 Smart Weapons for the Scottsdale Police Department, received and shipped in Q2)
Analyst comments: SSE +4.7% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey; tgt raised to $7 from $4), DRD +3.8% (upgraded to Overweight from Neutral at JP Morgan), GFI +1.9% (upgraded to Neutral from Sell at UBS), AEO +1.7% (upgraded to Outperform from Market Perform at Cowen), MSFT +1.4% (upgraded to Buy from Hold at Deutsche Bank), POWR+1.4% (upgraded to Buy at Maxim), KMB +0.9% (upgraded to Overweight from Equal Weight at Barclays)
In reaction to strong earnings/guidance: PDII +16.5%, GEVO +16%, TUBE +14.6%, HDP +11.7%, SYMX +10.9%, OPWR +10.3%, BIOC +7%, RENT +6.6%, ICCC +5.7%, CARA +5.6%, NVFY +5.5%, NEWR +5.3%, NVMI +4.7%, TSEM +4.6%, VIP +4.5%, ZBRA +3%, STKL +2.8%, ICL +2.3%, HCKT +1.9%, ELOS +1.9%, SSRI +1.8%, NAII +1.5%, MNGA +1.2%,VJET +1%, PCP +1%
M&A news: WPZ +26.1% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), OI +8.4% (acquires Vitro S.A.B's food and beverage business for $2.15 bln), WMB +8.4% (Williams (WMB) to acquire all public equity of Williams Partners L.P.), WX +5.9% (forms special committee of independent directors to evaluate the previously announced proposed takeover transaction), DHR +5.8% (acquires PLL; Danaher announces intention to separate into two independent, publicly traded companies), PLL +4.9% (to be acquired by Danaher (DHR) for $127.20 per share), SPKE +1.9% (announces acquisition of Oasis Energy)
Select oil/gas related names showing strength: STKL +2.8%, SDRL +2%, SD +1.3%, TOT +1.3%, BP +0.9%.
Other news: FCSC +25.8% ( recieves rare pediatric disease designation for FCX-007 from the FDA, to treat recessive dystrophic epidermolysis bullosa), AMCF +8.7% (announced that its previously scheduled NASDAQ listing hearing was cancelled after co pays outstanding fees; announced business updates, including entery into a non-binding letter of intent with Three Pillars PetroChem), MAGS +7.3% (recieves two new orders, worth a total of $13 mln), VRTX +7.2% (confirmed FDA Advisory Panel voted 12 to 1 to recommend approval of ORKAMBI to treat people with cystic fibrosis ages 12 and older), NBG +5.1% (optimism with Greece situation), QSR +3.2% (announces an $1.2 bln offering of first lien senior secured notes due 2022), DAL +2.7% (announces a new $5 billion share repurchase program, and a dividend increase of 50% to $0.135/share beginning in the September, 2015 quarter), NRF +2% (still checking), PPO +2% (disclosed that at a special meeting, its stockholders approved the proposal to adopt the Agreement and Plan of Merger with Asahi Kasei), AXP +1.5% (authorizes repurchase of up to 150 mln shares, announces 12% dividend increase), JBLU +1.2% (reports its preliminary traffic results for April 2015), DEO +1% (peer SAB Miller reported bte results), SNY +1% (exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease under the terms of an existing strategic global collaboration with Selecta Biosciences), TASR +1% (announces recent multiple orders, including up to 460 X2 Smart Weapons for the Scottsdale Police Department, received and shipped in Q2)
Analyst comments: SSE +4.7% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey; tgt raised to $7 from $4), DRD +3.8% (upgraded to Overweight from Neutral at JP Morgan), GFI +1.9% (upgraded to Neutral from Sell at UBS), AEO +1.7% (upgraded to Outperform from Market Perform at Cowen), MSFT +1.4% (upgraded to Buy from Hold at Deutsche Bank), POWR+1.4% (upgraded to Buy at Maxim), KMB +0.9% (upgraded to Overweight from Equal Weight at Barclays)